Cortex Pharmaceuticals, Inc. Announces Phase 1 Funding by

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cortex Pharmaceuticals, Inc. Announces Phase 1 Funding by the National Institute of Drug Abuse, National Institutes of Health, Under the Small Business Innovation Research Funding Award Program

GLEN ROCK, N.J., Sept. 24, 2014 (GLOBE NEWSWIRE) -- Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"), a leader in developing drugs for respiratory disorders, including drug-induced respiratory depression, as well as obstructive, central and mixed sleep apnea, announces that effective September 18, 2014, the Company has entered into an agreement with the National Institute of Drug Abuse valued at $148,583 and entitled "Novel Treatment of Drug-Induced Respiratory Depression." The funding is a Phase 1 award granted under the Small Business Innovation Research Funding Award Program. The purpose of this project is to determine the most useful injectable route of administration for CX1942, the Company's proprietary, soluble ampakine, a potential rescue medication for drug-induced respiratory depression and lethality. Under the terms of the funded program, preclinical studies will be performed in collaboration with Dr. David Fuller, of the University of Florida, and Dr. John Greer, of the University of Alberta.

Cortex will measure the potency, latency to onset and duration of action of CX1942 administered to rats, either prior to, simultaneously with, or subsequent to administration of either an opiate (morphine or fentanyl), a benzodiazepine (diazepam or alprazolam) in combination with an opiate (morphine or fentanyl), or a benzodiazepine (diazepam or alprazolam) in combination with ethanol. Three doses will be administered and studied intravenously, subcutaneously and intramuscularly. The data obtained from these studies will be used in order to finalize preclinical studies in preparation for initiating Phase 1 clinical studies.

In addition, the Company announces the appointment of John Greer, Ph.D. as Chairman of the Company's Scientific Advisory Board, which is currently in formation. Dr. Greer is the Director of the Neuroscience and Mental Health Institute at the University of Alberta. Dr. Greer received his Ph.D. at the University of Alberta and completed post-doctoral fellowships at the University of California, Los Angeles. He is an Alberta Innovates Health Sciences Senior Scientist and holds grants in two primary areas of research pertaining to neuromuscular control of breathing. The first funded initiative, regarding the neurochemical control of breathing, led to the development of ampakine therapy for overcoming respiratory depression caused by analgesics, anesthetics and certain disease states. The second funded initiative has provided the impetus for his laboratory to become prominent for its studies of the pathogenesis and etiology of the developmental anomaly, congenital diaphragmatic hernia. Dr. Greer is the inventor of the use patents licensed by Cortex for the use of ampakines that the Company is developing for the treatment of drug-induced respiratory depression and central and mixed-sleep apnea.

Arnold S. Lippa, Ph.D., Cortex Executive Chairman and Chief Executive Officer, stated, "We are pleased that the National Institute of Drug Abuse has favorably considered our application for funding and look forward to continuing our efforts to develop our proprietary soluble ampakine molecule, CX1942."

"We are also looking forward to continuing our work and collaborative efforts with Dr. John Greer, a key opinion leader in the field, as well as a creative and innovative thinker. His leadership and assistance in helping us to assemble a world-class scientific advisory board will be invaluable to Cortex in the future."

About Cortex Pharmaceuticals, Inc.

Cortex Pharmaceuticals, Inc. is a biopharmaceutical company currently engaged in the discovery and development of drugs for the treatment of respiratory disorders. Drug candidates are currently derived from two platforms, as described below.

The first platform is a class of compounds known as ampakines that act as positive allosteric modulators of AMPA glutamate receptors. Several ampakines in both oral and injectable form are being developed by Cortex for the treatment of drug induced respiratory depression caused by opiates and anesthetics. In preclinical and clinical studies, such drugs have shown preliminary efficacy in central sleep apnea and restored normal respiration without altering the analgesic effects of opiates or the anesthetic effects of drugs such as propofol. The Company's compounds belong to a new generation of ampakines that do not display the undesirable side effects displayed by previous compounds.

The second platform is the class of compounds known as cannabinoids, in particular, dronabinol. In a double-blind, placebo-controlled, dose-ascending Phase 2A clinical study conducted by the Company, dronabinol significantly improved measures of sleep apnea in a group of patients with obstructive sleep apnea. A larger 120 patient, double-blind, placebo-controlled Phase 2B study is currently being conducted by the University of Illinois and is being funded by the National Institutes of Health.

Additional information about Cortex and the matters discussed herein can be obtained on the Company's web-site at www.cortexpharm.com or in the Company's filings on EDGAR at www.sec.gov .

Special Note Regarding Forward-Looking Statements :   Certain statements included or incorporated by reference in this news release, including information as to the future financial or operating performance of the Company and its drug development programs, constitute forward-looking statements. The words "believe," "expect," "anticipate," "contemplate," "target," "plan," "intend," "continue," "budget," "estimate," "may," "schedule" and similar expressions identify forward-looking statements. Forward-looking statements include, among other things, statements regarding future plans, targets, estimates and assumptions. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by the Company, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Many factors could cause the Company's actual results to differ materially from those expressed or implied in any forward-looking statements made by, or on behalf of, the Company. Due to these various risks and uncertainties, actual events may differ materially from current expectations. Investors are cautioned that forward-looking statements are not guarantees of future performance and, accordingly, investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. Forward-looking statements are made as of the date of this news release and the Company disclaims any intent or obligation to update publicly such forward-looking statements, whether as a result of new information, future events or results or otherwise.

Company Contact: Jeff Margolis Vice-President and Secretary Telephone: (917) 834-7206 E-mail:

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Halfday Iced Tea Shakes Up U.S. Retail Scene

Updated Category News Views 150

Halfday's Meteoric Rise in the U.S. Market Sometimes, you pick up a can of iced tea, and it just changes the game. That’s exactly what Halfday is doing, stepping on the accelerator and leaving traditional iced tea brands in the dust. With their latest announcement, they've snagged the title of the fastest-growing modern tea brand in U.S. multi-outlet retail. It's the...

Continue Reading
Home Energy Tips: Embrace the Electrical Panel Shift

Updated Category News Views 75

Why Electrical Panels Matter More Than Ever Back in the day, electrical panels weren't exactly the star of the homeowner show. But times have changed, and those previously mundane boxes of switches and wires now demand a spotlight. Shifts in modern lifestyles have catapulted electrical systems into the spotlight, making upgrades a pressing conversation topic for savvy...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 203

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
HLTH USA 2026 Spotlights AI and Health Innovation

Updated Category News Views 113

The Pulse of Innovation at HLTH USA 2026 Diving headfirst into the heart of healthcare innovation, HLTH USA 2026 kicked off with gusto in Las Vegas. Discussions are swirling around AI advancements and the next generation of payer-provider collaboration. Who knew healthcare could be this thrilling? The event is already shaping up to be a powerhouse of change, buzzing with...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 25

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Ainstein Expands Kansas Operations Amid Sensor Demand Surge

Updated Category News Views 97

Ainstein's Expansion Conquers New Heights in Radar Tech Ainstein just cranked open a whole new chapter right in the heart of Kansas. And believe me, it's not your average ribbon-cutting story. This shiny new facility in Lenexa is locked and loaded to roll out 44,000 radar sensors a year. It's part of a no-nonsense plan to keep up with soaring demand for their tech across...

Continue Reading
DHL Leverages Robust Growth in Resilient Supply Chains

Updated Category News Views 158

Supply Chain Resilience: A Strategic Game Changer Market volatility's got its teeth in the game, and everyone in logistics knows it. DHL Supply Chain isn't just sitting back; they're riding the wave of change, snagging a 12% revenue bump in 2026. It's not your typical headline growth, either. More like the kind of growth that gets logistics gurus eyeing those contract...

Continue Reading
Surgical Tooth Extraction: When It’s Necessary

Updated Category News Views 144

Unpacking the Complexities of Tooth Extraction Ever wonder why some tooth extractions are a stroll in the park while others dive straight into surgical territory? It's all about positioning, condition, and what's lurking underneath. Thanks to Dr. Yadira Cardona-Rohena of Hamilton Mill Oral & Facial Surgery, we’ve got the lowdown. The Need for Skilled Surgical Techniques...

Continue Reading
NEDHSA Amplifies Tobacco-Free Push with 2026 Smokeout

Updated Category News Views 73

2026 Great American Smokeout: A Fresh Push Against Tobacco NEDHSA is sticking to its guns with a tobacco-free campaign that’s got deep roots. The 2026 Great American Smokeout, on November 19, not only highlights past efforts but looks to stir more folks into healthier habits. Beyond the campaign glitz, it’s about dragging a century-long bad habit further into the...

Continue Reading
Intel Hit by Securities Law Suit Amid PC Market Struggles

Updated Category News Views 85

Intel Faces the Music: Legal Battles Unfold So it seems Intel's got itself in a kettle of fish. The tech giant is being dragged into a courtroom dance, courtesy of a class action lawsuit led by DJS Law Group. Shareholders who snapped up Intel shares between July 23 and October 29, 2026, might be scratching their heads, wondering if they bought into a bit of a mirage. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding the Daily NAVs of WisdomTree ETFs

Updated Category News Views 110

Daily Net Asset Values of WisdomTree ETFs In the dynamic world of exchange-traded funds (ETFs), keeping track of daily Net Asset Values (NAVs) is crucial for investors looking to understand fund performance. WisdomTree Issuer plc has been a significant player in the ETF arena, offering various products that cater to diverse investment strategies. Each ETF represents a...

Continue Reading
How E-commerce Optimization Services Can Improve SEO Rankings

Updated Category Business Views 736

In the digital world, e-commerce companies flourish by being seen and recognized online. As competition grows fiercer, it becomes essential for e-commerce companies to distinguish themselves from competitors. E-commerce optimization services can boost rankings on search engines. Learning how to use e-commerce optimization strategies can help your business achieve business...

Continue Reading
Upcoming Financial Results Announcement by United Maritime

Updated Category News Views 191

Upcoming Financial Results Announcement by United Maritime GLYFADA, Greece — United Maritime Corporation (NASDAQ: USEA) is set to unveil its financial results for the first quarter ending on March 31. The announcement will be made before the market opens in New York on Thursday. Company Overview United Maritime Corporation is recognized as an international shipping...

Continue Reading
Texas Takes Legal Action Against Biden Over Lizard Protection

Updated Category News Views 91

Texas Attorney General Takes on Endangered Species Status In a noteworthy legal move, Texas Attorney General Ken Paxton has launched a lawsuit against the Biden administration over the recent endangered classification of the dunes sagebrush lizard. This designation, made by the U.S. Fish and Wildlife Service, has drawn significant criticism from Paxton, who contends that...

Continue Reading
Kevin T. Carter Takes the Helm as TCMA's Executive VP

Updated Category News Views 215

TCMA Welcomes a New Leader Trade Center Management Associates, LLC (TCMA, A Drew Company), has recently elevated Kevin T. Carter to the position of Executive Vice President. With a remarkable 45 years in the hospitality industry, Carter's extensive knowledge will guide the company’s strategic initiatives, ensuring robust operational leadership and exciting business...

Continue Reading